Current and historical daily PE Ratio for Jazz Pharmaceuticals PLC (
) from 2007 to Apr 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Jazz Pharmaceuticals PLC stock (JAZZ) PE ratio as of Apr 27 2024 is 17.89.
More Details
Jazz Pharmaceuticals PLC (JAZZ) PE Ratio (TTM) Chart
Jazz Pharmaceuticals PLC (JAZZ) PE Ratio (TTM) Historical Data
View and export this data going back to 2007. Start your Free Trial
Total 1217
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Jazz Pharmaceuticals PLC PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-27 | 17.9 | 2024-02-23 | 21.6 |
| 2024-04-26 | 17.9 | 2024-02-22 | 21.0 |
| 2024-04-25 | 17.6 | 2024-02-21 | 21.0 |
| 2024-04-24 | 17.7 | 2024-02-20 | 20.6 |
| 2024-04-23 | 17.9 | 2024-02-16 | 20.7 |
| 2024-04-22 | 17.8 | 2024-02-15 | 20.7 |
| 2024-04-19 | 18.0 | 2024-02-14 | 20.0 |
| 2024-04-18 | 17.9 | 2024-02-13 | 19.9 |
| 2024-04-17 | 17.5 | 2024-02-12 | 20.3 |
| 2024-04-16 | 17.8 | 2024-02-09 | 20.2 |
| 2024-04-15 | 18.1 | 2024-02-08 | 20.0 |
| 2024-04-12 | 18.1 | 2024-02-07 | 20.1 |
| 2024-04-11 | 18.5 | 2024-02-06 | 20.4 |
| 2024-04-10 | 18.6 | 2024-02-05 | 19.9 |
| 2024-04-09 | 18.6 | 2024-02-02 | 20.1 |
| 2024-04-08 | 18.8 | 2024-02-01 | 20.2 |
| 2024-04-05 | 19.0 | 2024-01-31 | 20.1 |
| 2024-04-04 | 18.8 | 2024-01-30 | 20.5 |
| 2024-04-03 | 19.1 | 2024-01-29 | 20.8 |
| 2024-04-02 | 19.2 | 2024-01-26 | 20.0 |
| 2024-04-01 | 19.4 | 2024-01-25 | 20.1 |
| 2024-03-28 | 19.7 | 2024-01-24 | 20.1 |
| 2024-03-27 | 19.7 | 2024-01-23 | 19.6 |
| 2024-03-26 | 19.3 | 2024-01-22 | 19.6 |
| 2024-03-25 | 19.7 | 2024-01-19 | 19.0 |
| 2024-03-22 | 19.9 | 2024-01-18 | 18.8 |
| 2024-03-21 | 20.3 | 2024-01-17 | 19.3 |
| 2024-03-20 | 20.4 | 2024-01-16 | 19.5 |
| 2024-03-19 | 20.4 | 2024-01-12 | 19.4 |
| 2024-03-18 | 20.2 | 2024-01-11 | 19.7 |
| 2024-03-15 | 19.8 | 2024-01-10 | 19.6 |
| 2024-03-14 | 19.3 | 2024-01-09 | 20.0 |
| 2024-03-13 | 19.2 | 2024-01-08 | 20.5 |
| 2024-03-12 | 18.9 | 2024-01-05 | 20.9 |
| 2024-03-11 | 19.1 | 2024-01-04 | 20.3 |
| 2024-03-08 | 19.2 | 2024-01-03 | 20.5 |
| 2024-03-07 | 19.0 | 2024-01-02 | 20.7 |
| 2024-03-06 | 19.1 | 2023-12-29 | 20.1 |
| 2024-03-05 | 19.4 | 2023-12-28 | 20.2 |
| 2024-03-04 | 19.2 | 2023-12-27 | 139.1 |
| 2024-03-01 | 19.4 | 2023-12-26 | 137.5 |
| 2024-02-29 | 19.4 | 2023-12-22 | 137.8 |
| 2024-02-28 | 21.2 | 2023-12-21 | 137.6 |
| 2024-02-27 | 21.6 | 2023-12-20 | 136.1 |
| 2024-02-26 | 21.7 | 2023-12-19 | 138.8 |
Jazz Pharmaceuticals PLC (JAZZ) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Jazz Pharmaceuticals PLC
NAICS : 325412
SIC : 2834
ISIN : IE00B4Q5ZN47
Compare
Compare
Traded in other countries / regions
JAZZ.USAJ7Z.GermanyJAZZ.Mexico IPO Date
2007-06-01Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers